

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

SIGA TECHNOLOGIES INC
Form 8-K
October 05, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 5, 2004

SIGA Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware -----	0-23047 -----	13-3864870 -----
(State or other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

420 Lexington Avenue, Suite 601, New York, New York -----	10170 -----
(Address of Principal Executive Offices)	(Zip Code)

(212) 672-9100

(Registrant's telephone number, including area code)

ITEM 7.01. Regulation FD Disclosure.

On October 5, 2004, SIGA Technologies, Inc., a Delaware corporation, issued a press release pursuant to which it announced that the Company's lead smallpox compound, SIGA-246, has demonstrated significant antiviral activity against several mouse models of poxvirus disease. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated in this Item 7.01 by reference.

ITEM 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit No. -----	Description -----
99.1	Press Release dated October 5, 2004.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

Thomas N. Konatich
Chief Financial Officer

Date: October 5, 2004

3

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release dated October 5, 2004.

4